Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.1%

3 terminated/withdrawn out of 49 trials

Success Rate

91.9%

+5.3% vs industry average

Late-Stage Pipeline

29%

14 trials in Phase 3/4

Results Transparency

32%

11 of 34 completed trials have results

Key Signals

5 recruiting11 with results

Enrollment Performance

Analytics

Phase 1

16(33.3%)

Phase 3

14(29.2%)

Phase 2

14(29.2%)

Early Phase 1

3(6.3%)

N/A

1(2.1%)

48Total

Phase 1(16)

Phase 3(14)

Phase 2(14)

Early Phase 1(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (49)

Showing 20 of 49 trials

NCT07228403Phase 3Active Not Recruiting

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Role: lead

NCT07733089Phase 1Recruiting

A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

Role: lead

NCT07721597Early Phase 1Recruiting

A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity

Role: lead

NCT03941236Phase 3Active Not Recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Role: lead

NCT07589686Phase 2Not Yet Recruiting

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Role: collaborator

NCT07682818Phase 1Recruiting

Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function

Role: lead

NCT07197944Phase 3Recruiting

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Role: lead

NCT07338214Phase 1Completed

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Role: lead

NCT06662539Phase 2Completed

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Role: lead

NCT06682975Phase 1Recruiting

A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants

Role: lead

NCT04881825Phase 3Active Not Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Role: lead

NCT03905707Phase 3Active Not Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Role: lead

NCT07076030Phase 1Completed

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

Role: lead

NCT06926842Phase 2Active Not Recruiting

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Role: lead

NCT05378672Phase 3Completed

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Role: lead

NCT03690206Phase 3Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Role: lead

NCT06758583Phase 1Completed

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Role: lead

NCT06000891Phase 1Terminated

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Role: lead

NCT04172441Phase 2Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Role: lead

NCT05788601Phase 2Active Not Recruiting

Dapiglutide for the Treatment of Obesity

Role: collaborator